{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:02:36Z","timestamp":1792047756541,"version":"4.4.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Chemical Biology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.chembiol.2026.04.008","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:40:10Z","timestamp":1779201610000},"page":"785-798.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancers"],"prefix":"10.1016","volume":"33","author":[{"given":"Wei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musaddeque","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Oeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Ingalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Giltnane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Blake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharada S.","family":"Labadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidhi","family":"Mody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"de Bruyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro M.","family":"Chibly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosai","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Hafner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-661X","authenticated-orcid":false,"given":"Ciara","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chembiol.2026.04.008_bib1","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/0092-8674(90)90422-B","article-title":"Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex","volume":"63","author":"Gaub","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2026.04.008_bib2","doi-asserted-by":"crossref","first-page":"16433","DOI":"10.1016\/S0021-9258(17)34025-5","article-title":"Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer","volume":"269","author":"Umayahara","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.chembiol.2026.04.008_bib3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1146\/annurev-cancerbio-061421-013525","article-title":"Next-Generation Estrogen Receptor\u2013Targeted Therapeutics","volume":"7","author":"Fernando","year":"2023","journal-title":"Ann. Rev. Cancer Biol."},{"key":"10.1016\/j.chembiol.2026.04.008_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0303-7207(02)00086-2","article-title":"Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells","volume":"192","author":"Sakamoto","year":"2002","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.chembiol.2026.04.008_bib5","doi-asserted-by":"crossref","first-page":"24172","DOI":"10.1074\/jbc.271.39.24172","article-title":"Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation","volume":"271","author":"McInerney","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.chembiol.2026.04.008_bib6","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1126\/science.1068537","article-title":"Molecular determinants for the tissue specificity of SERMs","volume":"295","author":"Shang","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2026.04.008_bib7","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.molcel.2017.02.008","article-title":"Structural and molecular mechanisms of cytokine-mediated endocrine resistance in human breast cancer cells","volume":"65","author":"Stender","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.chembiol.2026.04.008_bib8","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1101\/gad.1944810","article-title":"Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance","volume":"24","author":"Lupien","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.chembiol.2026.04.008_bib9","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.chembiol.2026.04.008_bib10","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/ng.2823","article-title":"Activating ESR1 mutations in hormone-resistant metastatic breast cancer","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.chembiol.2026.04.008_bib11","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1158\/0008-5472.CAN-13-1197","article-title":"D538G mutation in estrogen receptor-\u03b1: A novel mechanism for acquired endocrine resistance in breast cancer","volume":"73","author":"Merenbakh-Lamin","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.chembiol.2026.04.008_bib12","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","article-title":"Emergence of constitutively active estrogen receptor-\u03b1 mutations in pretreated advanced estrogen receptor-positive breast cancer","volume":"20","author":"Jeselsohn","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.chembiol.2026.04.008_bib13","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","article-title":"Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment","volume":"20","author":"Howell","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.chembiol.2026.04.008_bib14","first-page":"3867","article-title":"A potent specific pure antiestrogen with clinical potential","volume":"51","author":"Wakeling","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.chembiol.2026.04.008_bib15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2159-8290.CD-14-0697","article-title":"Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer","volume":"5","author":"van Kruchten","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.chembiol.2026.04.008_bib16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bcp.2011.03.031","article-title":"The turnover of estrogen receptor \u03b1 by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy","volume":"82","author":"Wardell","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.chembiol.2026.04.008_bib17","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.cell.2019.06.026","article-title":"Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility","volume":"178","author":"Guan","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2026.04.008_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/35050515","article-title":"FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent","volume":"3","author":"Stenoien","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.chembiol.2026.04.008_bib19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.cell.2016.02.067","article-title":"Steroid Receptors Reprogram FoxA1 Occupancy through Dynamic Chromatin Transitions","volume":"165","author":"Swinstead","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2026.04.008_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15896","article-title":"Single-molecule analysis of steroid receptor and cofactor action in living cells","volume":"8","author":"Paakinaho","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2026.04.008_bib21","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.cell.2014.01.062","article-title":"Single-molecule dynamics of enhanceosome assembly in embryonic stem cells","volume":"156","author":"Chen","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2026.04.008_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar2555","article-title":"Imaging dynamic and selective low-complexity domain interactions that control gene transcription","volume":"361","author":"Chong","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2026.04.008_bib23","doi-asserted-by":"crossref","first-page":"RP93183","DOI":"10.7554\/eLife.93183.3","article-title":"A high-throughput platform for single-molecule tracking identifies drug interaction and cellular mechanisms","volume":"12","author":"McSwiggen","year":"2025","journal-title":"eLife"},{"key":"10.1016\/j.chembiol.2026.04.008_bib24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1146\/annurev-biochem-072324-035226","article-title":"Assembly and dynamics of transcription initiation complexes","volume":"94","author":"Esbin","year":"2025","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.chembiol.2026.04.008_bib25","doi-asserted-by":"crossref","first-page":"11841","DOI":"10.1021\/acs.jmedchem.1c00847","article-title":"GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer","volume":"64","author":"Liang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2026.04.008_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo5959","article-title":"Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer","volume":"14","author":"Liang","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chembiol.2026.04.008_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.01500","article-title":"Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study","volume":"42","author":"Mart\u00edn","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.chembiol.2026.04.008_bib28","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/1078-0432.CCR-23-1796","article-title":"Phase Ia\/b Study of Giredestrant \u00b1 Palbociclib and \u00b1 Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced\/Metastatic Breast Cancer","volume":"30","author":"Jhaveri","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.chembiol.2026.04.008_bib29","doi-asserted-by":"crossref","first-page":"S1561","DOI":"10.1016\/j.annonc.2025.09.026","volume":"36","author":"Mayer","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.chembiol.2026.04.008_bib30","doi-asserted-by":"crossref","first-page":"GS1","DOI":"10.1158\/1557-3265.SABCS25-GS1-10","article-title":"Abstract GS1-10: Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial","volume":"32","author":"Bardia","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.chembiol.2026.04.008_bib31","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1530\/ERC-15-0287","article-title":"Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader","volume":"22","author":"Wardell","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.chembiol.2026.04.008_bib32","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.188051","article-title":"Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer","volume":"10","author":"Sherman","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.chembiol.2026.04.008_bib33","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/0008-5472.CAN-23-0694","article-title":"The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4\/6 Inhibitor Resistance","volume":"83","author":"Lawson","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.chembiol.2026.04.008_bib34","doi-asserted-by":"crossref","first-page":"22685","DOI":"10.1021\/acsomega.4c11023","article-title":"Discovery of palazestrant (OP-1250), a potent and orally bioavailable complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD)","volume":"10","author":"Ng","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.chembiol.2026.04.008_bib35","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1538-7445.AM2021-44","article-title":"Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer","volume":"81","author":"Snyder","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.chembiol.2026.04.008_bib36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd1031","article-title":"Tamoxifen: a most unlikely pioneering medicine","volume":"2","author":"Jordan","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.chembiol.2026.04.008_bib37","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.3853","article-title":"Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs","volume":"13","author":"Hafner","year":"2016","journal-title":"Nat. Methods"},{"key":"10.1016\/j.chembiol.2026.04.008_bib38","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/0960-0760(90)90418-K","article-title":"Therapeutic potential of pure antioestrogens in the treatment of breast cancer","volume":"37","author":"Wakeling","year":"1990","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.chembiol.2026.04.008_bib39","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(23)00268-1","article-title":"Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study","volume":"24","author":"Hurvitz","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.chembiol.2026.04.008_bib40","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s43018-024-00898-8","article-title":"ER\u03b1 dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER+ breast cancer","volume":"6","author":"Liang","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.chembiol.2026.04.008_bib41","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.chembiol.2026.04.008_bib42","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","article-title":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.chembiol.2026.04.008_bib43","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.chembiol.2026.04.008_bib44","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1200\/JCO.2024.42.16_suppl.1003","volume":"42","author":"Juric","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.chembiol.2026.04.008_bib45","doi-asserted-by":"crossref","first-page":"7977","DOI":"10.1073\/pnas.1337088100","article-title":"Systematic discovery of multicomponent therapeutics","volume":"100","author":"Borisy","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2026.04.008_bib46","first-page":"659","article-title":"Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens","volume":"9","author":"McDonnell","year":"1995","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.chembiol.2026.04.008_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103227","article-title":"Endocrine disrupting chemicals differentially alter intranuclear dynamics and transcriptional activation of estrogen receptor-\u03b1","volume":"24","author":"Bolt","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.chembiol.2026.04.008_bib48","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/2159-8290.CD-22-1387","article-title":"ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1-mutant breast cancer","volume":"14","author":"Kingston","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.chembiol.2026.04.008_bib49","first-page":"230","article-title":"Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens","volume":"10","author":"Montano","year":"1996","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.chembiol.2026.04.008_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126907","article-title":"Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ER\u03b1)","volume":"30","author":"Dragovich","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.chembiol.2026.04.008_bib51","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1471-2105-11-165","article-title":"Motif Enrichment Analysis: a unified framework and an evaluation on ChIP data","volume":"11","author":"McLeay","year":"2010","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.chembiol.2026.04.008_bib52","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1038\/nprot.2013.150","article-title":"Target analysis by integration of transcriptome and ChIP-seq data with BETA","volume":"8","author":"Wang","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.chembiol.2026.04.008_bib53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ng.730","article-title":"FOXA1 is a key determinant of estrogen receptor function and endocrine response","volume":"43","author":"Hurtado","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.chembiol.2026.04.008_bib54","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1242\/dev.043299","article-title":"FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis","volume":"137","author":"Bernardo","year":"2010","journal-title":"Development"},{"key":"10.1016\/j.chembiol.2026.04.008_bib55","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ceb.2008.02.003","article-title":"GATA-3 and the regulation of the mammary luminal cell fate","volume":"20","author":"Kouros-Mehr","year":"2008","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.chembiol.2026.04.008_bib56","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/jcp.21943","article-title":"GATA3 in development and cancer differentiation: cells GATA have it","volume":"222","author":"Chou","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.chembiol.2026.04.008_bib57","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1158\/2767-9764.CRC-23-0324","article-title":"Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer","volume":"3","author":"Malhi","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.chembiol.2026.04.008_bib58","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.1158\/0008-5472.CAN-20-0342","article-title":"Generalized additive mixed modeling of longitudinal tumor growth reduces bias and improves decision making in translational oncology","volume":"80","author":"Forrest","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.chembiol.2026.04.008_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00662395","article-title":"The future of new pure antiestrogens in clinical breast cancer","volume":"25","author":"Wakeling","year":"1993","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.chembiol.2026.04.008_bib60","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1038\/s41467-026-70335-0","article-title":"ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer","volume":"17","author":"Collier","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2026.04.008_bib61","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jsbmb.2011.02.001","article-title":"Aromatase, aromatase inhibitors, and breast cancer","volume":"125","author":"Chumsri","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.chembiol.2026.04.008_bib62","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nmeth.3252","article-title":"Orchestrating high-throughput genomic analysis with Bioconductor","volume":"12","author":"Huber","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.chembiol.2026.04.008_bib63","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/bioinformatics\/btq057","article-title":"Fast and SNP-tolerant detection of complex variants and splicing in short reads","volume":"26","author":"Wu","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.chembiol.2026.04.008_bib64","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2008-9-9-r137","article-title":"Model-based analysis of ChIP-Seq (MACS)","volume":"9","author":"Zhang","year":"2008","journal-title":"Genome Biol."},{"key":"10.1016\/j.chembiol.2026.04.008_bib65","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s43018-022-00337-6","article-title":"A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology","volume":"3","author":"Guillen","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.chembiol.2026.04.008_bib66","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.celrep.2013.08.022","article-title":"Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts","volume":"4","author":"Li","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.chembiol.2026.04.008_bib67","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1021\/acsmedchemlett.0c00224","article-title":"Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer","volume":"11","author":"Liang","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.chembiol.2026.04.008_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146021","article-title":"Dose-response analysis using R","volume":"10","author":"Ritz","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.chembiol.2026.04.008_bib69","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.drudis.2019.09.002","article-title":"Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls","volume":"24","author":"Vlot","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.chembiol.2026.04.008_bib70","author":"Vuong"}],"container-title":["Cell Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945626001431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945626001431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:51:16Z","timestamp":1781794276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451945626001431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2451945626001431"],"URL":"https:\/\/doi.org\/10.1016\/j.chembiol.2026.04.008","relation":{},"ISSN":["2451-9456"],"issn-type":[{"value":"2451-9456","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancers","name":"articletitle","label":"Article Title"},{"value":"Cell Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chembiol.2026.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}